Related Experiment Video

Updated: Jul 6, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

[Medical therapy in revascularized coronary artery disease patients]

Xiao-Hui Liu1, Xin DU, Jun-Ping Kang

  • 1Department of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Science, Beijing 100029, China.

Zhonghua Yi Xue Za Zhi
|March 26, 2008
PubMed

Insights

Medical therapy for revascularized coronary artery disease (CAD) patients is high during hospitalization but decreases significantly during follow-up, particularly for those undergoing coronary artery bypass grafting (CABG) or living outside Beijing.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Context:

  • Coronary artery disease (CAD) management requires effective secondary prevention post-revascularization.
  • Anzhen Hospital's DESIRE database tracked 2048 CAD patients from July 2003 to June 2004.
  • Follow-up averaged 587 days post-revascularization (percutaneous coronary intervention or coronary artery bypass grafting).

Purpose:

  • To evaluate the status of medical therapy in revascularized CAD patients.
  • To assess prescription rates of key secondary prevention medications.
  • To identify trends in medication use during hospitalization versus follow-up.

Summary:

  • High prescription rates for aspirin (93.9%), betablockers (88.9%), statins (67.7%), and ACE inhibitors (62.9%) were observed during hospitalization.
  • Combined therapy use was substantial, with 58.9% on aspirin, betablockers, and statins, and 39.7% on all four.
  • Prescription rates significantly declined during follow-up for all medications, especially in the coronary artery bypass grafting group and patients outside Beijing.

Impact:

  • Highlights a critical gap in sustained secondary prevention for CAD patients post-revascularization.
  • Suggests a need for improved adherence strategies and patient education, particularly for high-risk subgroups.
  • Informs clinical practice guidelines and healthcare policy to optimize long-term outcomes for CAD survivors.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...